Assertio Holdings, Inc.
US ˙ NasdaqCM ˙ US04546C2052

Introduction

This page provides a comprehensive analysis of the known insider trading history of Mark Strobeck. Insiders are officers, directors, or significant investors in a company. It is illegal for insiders to make trades in their companies based on specific, non-public information. This does not mean it is illegal for them to make any trades in their own companies. However, they must report all trades to the SEC via a Form 4. Despite these restrictions, academic research suggests that insiders - in general - tend to outperform the market in their own companies.

Average Trade Profitability

The average trade profitability is the average return of all the open market purchases made by the insider in the last three years. To calculate this, we examine every open-market, unplanned purchase made by the insider, excluding all trades that were marked as part of a 10b5-1 trading plan. We then calculate the average performance of those trades over 3, 6, and 12 months, averaging each of those durations to generate a final performance metric for each trade. Finally, we average all of the performance metrics to calculate a performance metric for the insider. This list only includes insiders that have made at least three trades in the last two years.

If this insiders trade profitability is "N/A", then the insider either has not made any open-market purchases in the last three years, or the trades they’ve made are too recent to calculate a reliable performance metric.

Update Frequency: Daily

See the list of most profitable insider traders.

Companies with Reported Insider Positions

The SEC filings indicate Mark Strobeck has reported holdings or trades in the following companies:

Security Title Latest Reported Holdings
US:RMTI / Rockwell Medical, Inc. President and CEO, Director 337,752
US:WINT / Windtree Therapeutics, Inc. Director 2,300
US:ASRT / Assertio Holdings, Inc. EVP & Chief Operating Officer 291,000
US:ZCOR / Zyla Life Sciences Chief Operating Officer 0
How to Interpret the Charts

The following charts show the stock performance of securities subsequent to each open-market, non-planned trade made by Mark Strobeck. Non-planned trade are trades that were not made as part of a 10b5-1 trading plan. The stock performance is charted as cumulative percent change in share price. For example, if an insider trade was made on January 1, 2019, the chart will show the daily percent change of the security to the present day. If the share price were to go from $10 to $15 during this time, the cumulative percent change in share price would be 50%. A change in price from $10 to $20 would be 100%, and a change in price of $10 to $5 would be -50%.

Ultimately, we are trying to determine how closely the insider’s trades correlate to excess returns (positive or negative) in the share price in order to see if the insider is timing their trades to profit from insider information. Consider the situation where an insider was doing this. In this situation, we would expect either (a) positive returns after purchases, or (b) negative returns after sales. In the case of (a), the PURCHASE chart would show a series of upwardly sloping curves, indicating positive returns after each purchase transaction. In the case of (b), the SALE chart would show a series of downward sloping curves, indicating negative returns after each sale transaction.

However, this alone is not enough to draw conclusions. If, for example, the share price of the company was in a non-cyclical climb over many years, then we would expect all the post-purchase plots to be upwardly sloping. Likewise, non-cyclical declines over many years would result in downward sloping post-trade plots. Neither of these charts would suggest insider trading activity.

The strongest indicator would be a situation where the share price was extremely cyclical, and there were both positive signals in the PURCHASE chart and negative plots on the SALE chart. This situation would be highly suggestive of an insider that was timing trades to their financial advantage.

Insider Purchases ASRT / Assertio Holdings, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASRT / Assertio Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASRT / Assertio Holdings, Inc. Insider Trades
Insider Sales ASRT / Assertio Holdings, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASRT / Assertio Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

ASRT / Assertio Holdings, Inc. Insider Trades
Insider Purchases RMTI / Rockwell Medical, Inc. - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASRT / Assertio Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RMTI / Rockwell Medical, Inc. Insider Trades
Insider Sales RMTI / Rockwell Medical, Inc. - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASRT / Assertio Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

RMTI / Rockwell Medical, Inc. Insider Trades
Insider Purchases WINTW / Windtree Therapeutics, Inc. - Equity Warrant - Short Term Profit Analysis

In this section, we analyze the profitability of every unplanned, open-market insider purchase made in ASRT / Assertio Holdings, Inc.. This analysis helps to understand if the insider consistently generates abnormal returns, and is worth following. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market purchases that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Max
Price at
Max
Max
Profit ($)
Max Return (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WINTW / Windtree Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Sales WINTW / Windtree Therapeutics, Inc. - Equity Warrant - Short Term Loss Analysis

In this section, we analyze the short-term loss avoidance of every unplanned, open-market insider sale made in ASRT / Assertio Holdings, Inc.. A consistent pattern of loss avoidance may suggest that future sale transactions may predict declines in price. This analysis is for one-year following each trade, and the results are theoretical.

The following table shows the most recent open market sales that were not part of an automatic trading plan.

Trade Date Ticker Insider Reported
Shares
Reported
Price
Adjusted
Shares
Adjusted
Price
Cost Basis Days to
Min
Price at
Min
Max Loss
Avoided ($)
Max Loss
Avoided (%)
There are no known unplanned open-market trades for this insider and security combination

Adjusted Price is the split-adjusted price. Adjusted Shares is the split-adjusted shares.

WINTW / Windtree Therapeutics, Inc. - Equity Warrant Insider Trades
Insider Trading History

This table shows the complete list of insider trades made by Mark Strobeck as disclosed to the Securities Exchange Commission (SEC).

File Date Tran Date Form Ticker Security Code 10b5-1 Shares Remaining Shares Percent
Change
Share
Price
Tran
Value
Remaining
Value
2025-07-03 2025-07-01 4/A RMTI ROCKWELL MEDICAL, INC.
Common Stock
S - Sale X -6,926 337,752 -2.01 0.82 -5,679 276,957
2025-07-02 2025-07-01 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
S - Sale X -6,926 337,752 -2.01 0.82 -5,679 276,957
2025-05-21 2025-05-20 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
A - Award 220,000 344,678 176.45
2025-04-02 2025-04-01 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
S - Sale X -6,926 124,678 -5.26 1.08 -7,480 134,652
2025-03-18 2025-03-17 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
F - Taxes -6,101 131,604 -4.43 1.77 -10,799 232,939
2025-03-18 2025-03-14 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
F - Taxes -7,333 137,705 -5.06 1.70 -12,466 234,098
2025-01-06 2025-01-02 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
S - Sale X -2,163 145,038 -1.47 2.06 -4,445 298,053
2024-10-02 2024-10-01 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
S - Sale X -2,163 147,201 -1.45 3.69 -7,971 542,465
2024-03-19 2024-03-17 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
F - Taxes -6,101 149,364 -3.92 1.40 -8,541 209,110
2024-03-15 2024-03-14 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
A - Award 100,000 155,465 180.29
2023-08-25 2023-08-23 4 WINT WINDTREE THERAPEUTICS INC /DE/
Common Stock
A - Award 2,300 2,300
2023-03-21 2023-03-17 4 RMTI ROCKWELL MEDICAL, INC.
Common Stock
A - Award 55,465 55,465
2020-05-22 2020-05-20 4 ASRT Assertio Holdings, Inc.
Stock Option (right to buy)
A - Award 291,000 291,000
2020-05-22 2020-05-20 4 ASRT Assertio Holdings, Inc.
Common Stock
A - Award 248,599 248,599
2020-05-21 2020-05-20 4 ZCOR Zyla Life Sciences
Stock Option (right to buy)
D - Sale to Issuer -116,400 0 -100.00
2020-05-21 2020-05-20 4 ZCOR Zyla Life Sciences
Common Stock
D - Sale to Issuer -180,864 0 -100.00
2020-03-26 2020-03-26 4 ZCOR Zyla Life Sciences
Restricted Stock Units
M - Exercise 29,000 0 -100.00
2020-03-26 2020-03-26 4 ZCOR Zyla Life Sciences
Restricted Stock Units
M - Exercise 33,000 0 -100.00
2020-03-26 2020-03-26 4 ZCOR Zyla Life Sciences
Common Stock
F - Taxes -17,038 44,962 -27.48 1.60 -27,261 71,939
2020-03-26 2020-03-26 4 ZCOR Zyla Life Sciences
Common Stock
M - Exercise 29,000 62,000 87.88 1.60 46,400 99,200
2020-03-26 2020-03-26 4 ZCOR Zyla Life Sciences
Common Stock
M - Exercise 33,000 33,000 1.60 52,800 52,800
2020-03-05 2020-03-04 4 ZCOR Zyla Life Sciences
Stock Option (right to buy)
A - Award 116,400 116,400
2020-03-05 2020-03-04 4 ZCOR Zyla Life Sciences
Common Stock
A - Award 79,800 79,800
2020-03-02 2020-03-01 4 ZCOR Zyla Life Sciences
Restricted Stock Units
M - Exercise 32,670 0 -100.00
2020-03-02 2020-03-01 4 ZCOR Zyla Life Sciences
Restricted Stock Units
M - Exercise 43,065 0 -100.00
2020-03-02 2020-03-01 4 ZCOR Zyla Life Sciences
Common Stock
F - Taxes -20,812 54,923 -27.48 1.50 -31,218 82,384
2020-03-02 2020-03-01 4 ZCOR Zyla Life Sciences
Common Stock
M - Exercise 32,670 75,735 75.86 1.50 49,005 113,602
2020-03-02 2020-03-01 4 ZCOR Zyla Life Sciences
Common Stock
M - Exercise 43,065 43,065 1.50 64,598 64,598
2019-03-28 2019-03-26 4 EGLT Egalet Corp
Common Stock
A - Award 33,000 120,000 37.93
2019-03-28 2019-03-26 4 EGLT Egalet Corp
Common Stock
A - Award 87,000 87,000
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Stock Option (Right to Buy)
D - Sale to Issuer -100,000 0 -100.00
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Stock Option (Right to Buy)
D - Sale to Issuer -100,000 0 -100.00
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Stock Option (Right to Buy)
D - Sale to Issuer -115,000 0 -100.00
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Stock Option (Right to Buy)
D - Sale to Issuer -40,000 0 -100.00
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Common Stock
D - Sale to Issuer -80,000 0 -100.00
2019-02-04 2019-01-31 4 EGLT Egalet Corp
Common Stock
D - Sale to Issuer -237,080 0 -100.00
2018-06-15 2018-06-13 4 EGLT Egalet Corp
Common Stock
A - Award 225,000 317,080 244.35
2018-03-08 2018-03-06 4 EGLT Egalet Corp
Common Stock
A - Award 80,000 92,080 662.25
2017-10-03 2017-10-02 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 12,080 -41.87 1.29 -11,223 15,583
2017-07-05 2017-06-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 20,780 -29.51 2.39 -20,793 49,664
2017-06-12 2017-06-08 4 EGLT Egalet Corp
Stock Option (Right to Buy)
A - Award 100,000 100,000
2017-03-31 2017-03-31 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 29,480 -22.79 5.11 -44,457 150,643
2017-01-04 2016-12-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 38,180 -18.56 7.81 -67,947 298,186
2016-12-08 2016-12-06 4 EGLT Egalet Corp
Stock Option (Right to Buy)
A - Award 100,000 100,000
2016-10-03 2016-09-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -25,000 46,880 -34.78 7.59 -189,750 355,819
2016-10-03 2016-09-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 71,880 -10.80 7.55 -65,685 542,694
2016-07-05 2016-06-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 80,580 -9.74 4.68 -40,716 377,114
2016-04-04 2016-03-31 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 89,280 -8.88 6.70 -58,290 598,176
2016-01-05 2015-12-31 4 EGLT Egalet Corp
Common Stock
S - Sale X -8,700 97,980 -8.16 10.40 -90,480 1,018,992
2015-11-24 2015-11-20 4 EGLT Egalet Corp
Stock Option (Right to Buy)
A - Award 115,000 115,000
2015-10-02 2015-09-30 4 EGLT Egalet Corp
Common Stock
S - Sale X -5,220 106,680 -4.66 12.56 -65,563 1,339,901
2015-07-02 2015-07-01 4 EGLT Egalet Corp
Common Stock
S - Sale X -10,440 111,900 -8.53 12.98 -135,511 1,452,462
2015-01-05 2015-01-02 4 EGLT Egalet Corp
Common Stock
S - Sale X -3,480 122,340 -2.77 5.09 -17,713 622,711
2014-12-08 2014-12-04 4 EGLT Egalet Corp
Stock Option (Right to Buy)
A - Award 40,000 40,000
2014-08-14 2014-08-13 4 EGLT Egalet Corp
Common Stock
S - Sale X -2,635 125,280 -2.06 9.15 -24,110 1,146,312
2014-08-14 2014-08-12 4 EGLT Egalet Corp
Common Stock
S - Sale X -2,500 127,915 -1.92 9.26 -23,150 1,184,493
2014-08-12 2014-08-11 4 EGLT Egalet Corp
Common Stock
S - Sale X -3,300 130,415 -2.47 10.16 -33,528 1,325,016
2014-08-12 2014-08-08 4 EGLT Egalet Corp
Common Stock
S - Sale X -2,400 133,715 -1.76 10.45 -25,080 1,397,322
2014-08-08 2014-08-07 4 EGLT Egalet Corp
Common Stock
S - Sale X -1,200 136,115 -0.87 10.90 -13,080 1,483,654
2014-08-08 2014-08-06 4 EGLT Egalet Corp
Common Stock
S - Sale X -1,885 137,315 -1.35 11.89 -22,413 1,632,675
2014-02-12 2014-02-11 4 EGLT Egalet Corp
Common Stock
A - Award 139,200 139,200
P
Open market or private purchase of non-derivative or derivative security
S
Open market or private sale of non-derivative or derivative security
A
Grant, award, or other acquisition of securities from the company (such as an option)
C
Conversion of derivative
D
Sale or transfer of securities back to the company
F
Payment of exercise price or tax liability using portion of securities received from the company
G
Gift of securities by or to the insider
K
Equity swaps and similar hedging transactions
M
Exercise or conversion of derivative security received from the company (such as an option)
V
A transaction voluntarily reported on Form 4
J
Other (accompanied by a footnote describing the transaction)